We are committed to the identification, in-licensing and systematic development of promising therapeutic candidates.

Via in-licensing initiatives, we are eager to evaluate therapeutic frontiers in late-preclinical and clinical stages of development with an emphasis on new chemical entities and biologics in the field of oncology. Our unique partnering strategy allows integration of novel technologies using various business models making the partnering process meaningful and attractive for both sides.

Are you a potential partner?

For more information please contact: